Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00317681
Other study ID # AMG 001
Secondary ID 2004-005020-41
Status Completed
Phase Phase 2
First received April 21, 2006
Last updated September 7, 2007
Start date August 2005
Est. completion date February 2007

Study information

Verified date September 2007
Source Heinrich-Heine University, Duesseldorf
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of topical tacrolimus in different subtypes of cutaneous lupus erythematosus. As shown by several groups activated memory T lymphocytes play a key role in the pathogenesis of lupus erythematosus. Tacrolimus targets T lymphocytes and suppresses their activation by inhibiting the expression of cytokine genes, such as IL-2. Therefore, treatment of cutaneous lupus erythematosus with topical tacrolimus might result in an improvement of skin lesions in such patients.


Description:

In patients with cutaneous lupus erythematosus (CLE), topical corticosteroids are the mainstay of treatment; however, a long-term use can lead to numerous side effects including skin atrophy. Recently, topical tacrolimus has been suggested to be effective in patients with different manifestations of CLE as single or additive therapy. Its anti-inflammatory effect can be explained by inhibition of calcineurin and suppression of proinflammatory cytokines such as interleukins-2, -3, -4, granulocyte colony-stimulating factor, and tumour necrosis factor alpha. In this study, we evaluate the efficacy of tacrolimus in 30 patients with different forms of CLE (ACLE, SCLE, DLE, LET). During a period of 3 months tacrolimus ointment and its placebo are applied on two separate skin lesions. Clinical follow-up examinations including photo documentation are performed every 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Cutaneous lupus erythematosus confirmed by histological analysis

- Topical use of glucocorticosteroids stopped at least two weeks before the start of the study

- Presence of two primary skin lesions with a clinical score = 1

- Written informed consent available prior to any screening procedures

Exclusion Criteria:

- Systemic medication if taken for lupus erythematosus (e.g. chloroquine or hydroxychloroquine) started at least 6 months prior to the beginning of the study

- Women of childbearing potential using inadequate birth control measures

- Pregnancy and lactation

- Known hypersensitivity to tacrolimus or any of the excipients

- Patients receiving systemic immunosuppressive drugs and cytotoxic agents other than antimalarial agents

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Tacrolimus ointment


Locations

Country Name City State
Germany Heinrich-Heine-University of Duesseldorf, Department of Dermatology Duesseldorf NRW

Sponsors (1)

Lead Sponsor Collaborator
Heinrich-Heine University, Duesseldorf

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Bacman D, Tanbajewa A, Megahed M, Ruzicka T, Kuhn A. [Topical treatment with tacrolimus in lupus erythematosus tumidus]. Hautarzt. 2003 Oct;54(10):977-9. German. — View Citation

Kuhn A, Gensch K, Ständer S, Bonsmann G. [Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification]. Hautarzt. 2006 Mar;57(3):251-67; quiz 268. German. — View Citation

Kuhn A, Gensch K, Ständer S, Bonsmann G. [Cutaneous lupus erythematosus. Part 2: diagnostics and therapy]. Hautarzt. 2006 Apr;57(4):345-8; quiz 359. German. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in skin lesions of patients with CLE before (begin of study) and after treatment (end of study) evaluated by a clinical score
See also
  Status Clinical Trial Phase
Completed NCT01776190 - Low-dose UVA1 Radiation in Cutaneous Lupus Patients N/A
Completed NCT00420173 - Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) N/A
Terminated NCT04809623 - Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) Phase 1
Completed NCT01300208 - To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Phase 2
Terminated NCT01470313 - A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Phase 1
Completed NCT01146444 - Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) N/A
Completed NCT03134222 - Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Phase 2
Completed NCT01629784 - Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus N/A
Completed NCT00470912 - Sunscreen RV 2457C in Photoinduced CLE Phase 3
Completed NCT01841619 - IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Phase 0
Completed NCT00523588 - Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Phase 2
Recruiting NCT06411106 - Deep Phenotyping of Cutaneous Lupus Erythematosus N/A
Not yet recruiting NCT06015737 - A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Phase 3
Terminated NCT01498406 - Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Phase 2
Completed NCT04647708 - Study of M5049 in CLE and SLE Participants Phase 1
Completed NCT03817424 - A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Phase 1
Active, not recruiting NCT03260166 - Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Phase 2
Completed NCT04781816 - Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus Phase 2